跳至主要内容
临床试验/NCT07069387
NCT07069387进行中(未招募)不适用

Comprehensive Digital Adherence and Remote Engagement to Optimise Treatment Adherence for Tuberculosis Patients (CARE-TB Study) in Selangor, Malaysia: An Effectiveness-Implementation Science Study

University of Malaya1 个研究点 分布在 1 个国家目标入组 81 人开始时间: 2025年4月7日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
81
试验地点
1
主要终点
Medication adherence (Binary outcome)

研究概览

简要总结

The gold standard for tuberculosis (TB) treatment support requires directly observed therapy (DOT), which means a trained health worker observes the patient swallow each dose of medication every day for 2 months. Despite the practice of DOT in Malaysia, 1 in 20 patients are loss-to-follow-up and non-adherent to treatment. Sub-optimal adherence due to poor treatment acceptability and social desirability promotes TB treatment failure, disease relapse, on-going transmission, drug resistance, and death. Telemedicine offers a flexible and less invasive option to support TB treatment adherence. Despite 97% internet and smartphone penetration rates, the practical implementation of digital adherence strategies to support and monitor TB treatment remains untested in Malaysia. The investigators propose to design, implement, and measure the effectiveness of a comprehensive, pharmacist-led digital solution for TB treatment support called CARE-TB which combines a package of asynchronous video-observed therapy, digital reminders, telecounselling and e-learning. In this multi-method effectiveness-implementation (Type 2) study using the Exploration, Preparation, Implementation and Sustainment (EPIS) framework, the investigators aim 1) To identify patient and provider-level facilitators and barriers to CARE-TB adoption via qualitative evaluation and to design a stakeholder-informed implementation strategy, (2) To assess effectiveness of CARE-TB strategy by evaluating (i) implementation outcomes, (ii) patient health outcomes, and (iii) service outcomes, and (3) To evaluate the cost-effectiveness of CARE-TB compared to standard of care from a societal perspective. This study will leverage digital platforms to expand the reach of TB adherence support, enhance adherence to TB treatment and improve treatment completion rates, while utilising existing personnel and resources in among the busiest TB treatment centres in the country.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Microbiologically confirmed pulmonary TB (smear- or culture-positive PTB)
  • •18 years old or older
  • •Able to give consent and physically able to participate in the study
  • •Own a video-recording device with internet connectivity
  • •Within the first 3 weeks of intensive phase TB treatment

排除标准

  • •Complicated TB disease including TB meningitis, TB bone/joint, and disseminated TB with planned treatment duration of 9 to 12 months.
  • •Confirmed or suspected drug-resistant (DR)-TB
  • •Documented cognitive, motor, or visual disability that will hinder video device use and lack assistance of a caretaker
  • •Receiving injectable anti-TB drugs
  • •Incarceration or other involuntary detention

研究组 & 干预措施

Standard care arm

Active Comparator

Directly observed therapy (healthcare or caretaker-based)

干预措施: Standard Care (Behavioral)

CARE-TB arm

Experimental

CARE-TB package includes pharmacist-led asynchronous video observed therapy, digital medication reminders, telecounselling and e-learning for patients.

干预措施: CARE-TB digital adherence package (Behavioral)

结局指标

主要结局

Medication adherence (Binary outcome)

时间窗: 8 weeks following enrollment

Completed ≥ 80% scheduled observations during the 8 weeks following enrolment.

次要结局

  • Adherence rate (Continuous outcome)(8 weeks following enrolment)
  • Proportion of TB treatment completion, death, loss to follow up, and hospitalization(From enrolment till 6 months or treatment completion/ termination)
  • TB cure rate(At 6 months of treatment)
  • Adverse event reporting(From enrolment till 6 months of treatment)
  • EQ-5D-5L Health-related Quality of Life (HRQoL)(At baseline, 2 months and 6 months of treatment)
  • SF-12 Health-related Quality of Life (HRQoL)(At baseline and 2 months of treatment)
  • Perceived acceptability, feasibility, and fit of the intervention (Qualitative measure)(After 6 months of implementation phase)
  • Implementation Outcomes: Acceptability, Feasibility, Appropriateness (Quantitative measure)(At 2 months and 6 months of treatment)
  • Adoption rate(Through study completion, an average of 1 year)
  • Patient fidelity to intervention(8 weeks following enrolment)
  • Healthcare providers (HCP) fidelity to intervention(8 weeks following enrolment)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验